Search results for "Guideline"

showing 10 items of 800 documents

Interdisciplinary consensus on the uses and technique of MR-guided vacuum-assisted breast biopsy (VAB): results of a European consensus meeting.

2009

Abstract Purpose Quality assurance of MR-guided vacuum-assisted breast biopsy (VAB). Method A consensus was achieved based on the existing literature and experience of an interdisciplinary group comprising European specialists in breast imaging and VAB. Results Full imaging work-up must be completed according to existing standards before an indication for MR-guided VAB is established. The procedure should be reserved for lesions demonstrable by MRI alone. Acquisition of >24 cores (11-Gauge) should be routinely attempted, with the intention of sufficiently removing small lesions for accurate diagnosis. Following biopsy the patient should be re-imaged to demonstrate the biopsy site and its pr…

Breast biopsymedicine.medical_specialtymedicine.diagnostic_testBreast imagingbusiness.industryBiopsy NeedleMEDLINEGeneral MedicineAuditMagnetic Resonance ImagingSurgeryEuropeBiopsy SiteSurgery Computer-AssistedBiopsyVacuum-assisted breast biopsyPractice Guidelines as TopicmedicineHumansRadiology Nuclear Medicine and imagingMedical physicsSampling (medicine)businessEuropean journal of radiology
researchProduct

Técnicas fibrobroncoscópicas especiales: lavado broncoalveolar, biopsia bronquial y biopsia transbronquial

2005

Este artículo completa las recomendaciones sobre el uso y aplicaciones del broncoscopio flexible en la infancia, del Grupo de Técnicas de la Sociedad Española de Neumología Pediátrica, incluyendo los procedimientos que, con fines diagnósticos y ocasionalmente terapéuticos, se aplican con mayor frecuencia durante la práctica de la broncoscopia flexible: el lavado broncoalveolar y las biopsias bronquial y transbronquial. Se realizan también recomendaciones para la práctica del lavado broncoalveolar no broncoscópico.Se revisan las indicaciones, contraindicaciones, recursos materiales, el cuidado y monitorización del paciente previo, durante y posterior al procedimiento, y las complicaciones de…

Bronchoalveolar lavagemedicine.medical_specialtymedicine.diagnostic_testbusiness.industryFlexible bronchoscopyBronchialbiopsyGuidelineGuidelinesPediatricsRJ1-570Bronchoalveolar lavageTransbronchial biopsyPediatrics Perinatology and Child HealthBiopsymedicineBronchial BiopsyRadiologyTransbronchial biopsybusinessChildrenFlexible bronchoscopyPulmonologistsAnales de Pediatría
researchProduct

Overall asthma control: the relationship between current control and future risk.

2009

Background Asthma guidelines emphasize both maintaining current control and reducing future risk, but the relationship between these 2 targets is not well understood. Objective This retrospective analysis of 5 budesonide/formoterol maintenance and reliever therapy (Symbicort SMART Turbuhaler ∗ ∗Symbicort SMART and Turbuhaler are trademarks owned by AstraZeneca. Neither the Symbicort SMART posology nor the dry powder formulation Turbuhaler are currently approved in the United States.) studies assessed the relationship between asthma control questionnaire (ACQ-5) and Global Initiative for Asthma-defined clinical asthma control and future risk of instability and exacerbations. Methods The perc…

BudesonideAdultMalemedicine.medical_specialtyExacerbationAdolescentImmunologyYoung AdultAdrenal Cortex HormonesInternal medicineFormoterol FumarateSurveys and QuestionnairesAdministration InhalationmedicineImmunology and AllergyBudesonide Formoterol Fumarate Drug CombinationHumansAnti-Asthmatic AgentsRisk factorBudesonideChildAsthmaAgedRandomized Controlled Trials as TopicRetrospective StudiesAged 80 and overInhalationbusiness.industryAdrenergic beta-AgonistsMiddle Agedmedicine.diseaseAsthmaMarkov ChainsDrug CombinationsAsthma Control QuestionnaireEthanolaminesChild PreschoolPractice Guidelines as TopicPhysical therapyFormoterol FumarateFemaleFormoterolbusinessmedicine.drugThe Journal of allergy and clinical immunology
researchProduct

Routine Use of Budesonide/Formoterol Fixed Dose Combination in Elderly Asthmatic Patients: Practical Considerations

2017

Asthma has been demonstrated to be as common in the elderly as in younger age groups. Although no specific recommendations exist to manage the disease differently in older individuals, functional features and clinical presentations may be affected by age per se, and by age-related conditions, such as comorbidities and polypharmacy. In this review article, we aimed to explore the efficacy and safety in elderly asthmatic patients of one of the most currently used inhaled treatments for asthma, that is, the fixed-dose combination of budesonide/formoterol. We attempted to address some practical questions that are relevant to the daily practice of clinicians. We focused on the efficacy and real-…

BudesonideGeriatrics & GerontologyDatabases Factuallaw.invention0302 clinical medicineRandomized controlled trialRELIEVER THERAPYlawBudesonide Formoterol Fumarate Drug CombinationDrug InteractionsPharmacology (medical)Anti-Asthmatic AgentsPharmacology & Pharmacy030212 general & internal medicineEMPHYSEMATOUS LUNGSGeriatricsPRIMARY-CAREGeriatrics and Gerontology Pharmacology (medical)Middle AgedRANDOMIZED CONTROLLED-TRIALSINGLE INHALERTreatment OutcomeDrug InteractionPractice Guidelines as TopicLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialtySettore MED/10 - Malattie Dell'Apparato RespiratorioOBSTRUCTIVE PULMONARY-DISEASE03 medical and health sciencesAdministration InhalationmedicineAnti-Asthmatic AgentHumansOLDER-PEOPLEIntensive care medicineAgedAsthmaPolypharmacyAIRWAY CLEARANCEScience & Technologybusiness.industryDRY POWDER INHALERSmedicine.diseaseAsthma030228 respiratory systemBudesonide/formoterolLUNG DEPOSITIONGeriatricsPhysical therapyIndacaterol1115 Pharmacology And Pharmaceutical SciencesFormoterolGeriatrics and GerontologybusinessDrugs & Aging
researchProduct

Cancer screening and health system resilience: Keys to protecting and bolstering preventive services during a financial crisis

2012

The aim of this paper is to elucidate the rationale for sustaining and expanding cost-effective, population-based screening services for breast, cervical and colorectal cancers in the context of the current financial crisis. Our objective is not only to promote optimal delivery of high-quality secondary cancer prevention services, but also to underline the importance of strengthening comprehensive cancer control, and with it, health system response to the complex care challenges posed by all chronic diseases. We focus primarily on issues surrounding planning, organisation, implementation and resources, arguing that given the growing cancer burden, policymakers have ample justification for e…

BudgetsCancer ResearchEconomic growthNational Health ProgramsCost-Benefit Analysismedia_common.quotation_subjectPopulationPublic policyContext (language use)Population healthFinancial managementPredictive Value of TestsNeoplasmsPreventive Health ServicesCancer screeningHumansMass ScreeningOrganizational ObjectivesMedicinePolicy Makingeducationmedia_commoneducation.field_of_studyGovernmentEvidence-Based Medicinebusiness.industryHealth PolicyEnvironmental resource managementHealth Care CostsHealth PlanningEconomic RecessionOncologyPractice Guidelines as TopicPsychological resiliencebusinessDelivery of Health CareEuropean Journal of Cancer
researchProduct

A Guideline-based Survey Of COPD Management Of Pneumologists In Germany

2010

COPDmedicine.medical_specialtybusiness.industryFamily medicinemedicineGuidelinemedicine.diseasebusinessB36. CHRONIC OBSTRUCTIVE PULMONARY DISEASE NON-PHARMACOLOGIC TREATMENTS AND QUALITY OF LIFE
researchProduct

Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study.

2021

Abstract Background and aims Central and Eastern Europe (CEE) is a largely understudied region, despite having the highest cardiovascular disease mortality in Europe. This analysis aimed to assess the proportion of patients in CEE who achieved their LDL-C goals based on individual cardiovascular risk recommended by the 2016 and 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines. Methods The DA VINCI study was a cross-sectional observational study of primary and secondary prevention patients receiving lipid-lowering therapy across Europe between June 2017 and November 2018. Results In total, 2154 patients were enrolled from the Czech Republic (n = 509…

COUNTRIESmedicine.medical_specialtyDyslipidaemiaAtherosclerosis; Cardiovascular; Dyslipidaemia; Low-density lipoprotein cholesterolCardiac & Cardiovascular SystemsIMPACTDYSLIPIDEMIACardiovascularGUIDELINESLipid-lowering therapySecondary CareSecondary careRisk FactorsCARDIOVASCULAR RISK-FACTORSMANAGEMENTMedicineHumansLow-density lipoprotein cholesterolCORONARY-HEART-DISEASE1102 Cardiorespiratory Medicine and HaematologyDyslipidemiasSecondary preventionLipid managementScience & Technologybusiness.industryDisease mortality1103 Clinical SciencesAtherosclerosisPREVENTIONLipidsPREVALENCEClinical PracticeEuropeCross-Sectional StudiesTreatment OutcomePeripheral Vascular DiseaseCardiovascular System & HematologyCardiovascular DiseasesFamily medicineEuropean atherosclerosis societyCardiovascular System & CardiologyObservational studyPolandHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessLife Sciences & BiomedicineAtherosclerosis
researchProduct

COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the …

2021

High mortality rates in elderly patients or in those with underlying chronic illnesses and/or a compromised immune system is a peculiar feature of COVID-19 infection. The possible coexistence of a cancer and COVID-19 infection in the same individual prompted concerns regarding their synergistic effect on prognosis. In order to balance patients’ needs with the risks related to the infection, the question oncologists have asked from the beginning of the first wave of the pandemic has been: ‘how can we deal with COVID-19 infection in cancer patients?’ In pursuing its mission, the Associazione Italiana Oncologia Medica (AIOM) has made every possible effort to support cancer patients, health car…

Cancer Research2019-20 coronavirus outbreakmedicine.medical_specialtyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)FAVO Federazione delle Associazioni di Volontariato in OncologiaReviewWHO World Health OrganizationCIPOMO Italian College of Primary Hospital Medical OncologistsSICO Società Italiana di Chirurgia OncologicaMedicalNeoplasmsHealth carePandemicMedicinecancerCentral Venous CathetersHumansFNOPI Federazione Nazionale Ordini Professioni InfermieristicheSocieties MedicalAIRO Associazione Italiana Radioterapia e Oncologia clinicaOncologistsClinical Trials as Topictreatmentbusiness.industryHigh mortalityAIOM Associazione Italiana di Oncologia medicaCancerNeoplasms therapyAIOM; cancer; COVID-19; treatment; vaccination; Central Venous Catheters; Clinical Trials as Topic; Humans; Influenza Vaccines; Oncologists; Practice Guidelines as Topic; COVID-19; COVID-19 Vaccines; Neoplasms; Societies MedicalCOVID-19medicine.diseasevaccinationCOMU College of University Medical OncologistsOncologyInfluenza VaccinesFamily medicineFOCE ConFederazione degli Oncologi Cardiologi e EmatologiPractice Guidelines as TopicESMO European Society for Medical OncologybusinessSocietiesSIPO Società Italiana di Psico-OncologiaAIOMESMO open
researchProduct

EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe

2013

Contains fulltext : 125368.pdf (Publisher’s version ) (Closed access) BACKGROUND: Care for patients with colon and rectal cancer has improved in the last twenty years however still considerable variation exists in cancer management and outcome between European countries. Therefore, EURECCA, which is the acronym of European Registration of cancer care, is aiming at defining core treatment strategies and developing a European audit structure in order to improve the quality of care for all patients with colon and rectal cancer. In December 2012 the first multidisciplinary consensus conference about colon and rectum was held looking for multidisciplinary consensus. The expert panel consisted of…

Cancer ResearchDelphi TechniqueColorectal cancerDelphi methodPhysician's Practice PatternsGUIDELINESSTAGESurgical oncologyMinimal invasive surgeryTeams in the workplacePractice Patterns Physicians'Rectal cancerCooperative BehaviorSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAddc:616Neoadjuvant radiotherapyMultidisciplinary teamTranslational research Tissue engineering and pathology [ONCOL 3]Total mesorectal excisionQuality assuranceColon cancerNeoadjuvant chemoradiotherapyEuropeColon cancer; Consensus; Delphi method; Minimal invasive surgery; Multidisciplinary team; Neoadjuvant chemoradiotherapy; Neoadjuvant radiotherapy; Quality assurance; Rectal cancerTreatment OutcomeOncologySURVIVALGuideline AdherenceColorectal NeoplasmsEuropaEUROCARECare of the sickCOUNTRIESmedicine.medical_specialtyMARGINEvidence-based practiceConsensusDelphi methodAuditDIAGNOSISSDG 3 - Good Health and Well-beingCàncer colorectalTreball en equipmedicineHumansCura dels malaltsPREOPERATIVE RADIOTHERAPYQuality of Health CarePatient Care Teambusiness.industryTOTAL MESORECTAL EXCISIONCancerAuditmedicine.diseaseColorectal cancerSurgeryOncology nursingFamily medicineREGISTRYInterdisciplinary Communicationbusiness
researchProduct

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

2011

Abstract Purpose: To facilitate development of innovative immunotherapy approaches, especially for treatment concepts exploiting the potential benefits of personalized therapy, there is a need to develop and validate tools to identify patients who can benefit from immunotherapy. Despite substantial effort, we do not yet know which parameters of antitumor immunity to measure and which assays are optimal for those measurements. Experimental Design: The iSBTc-SITC (International Society for Biological Therapy of Cancer-Society for Immunotherapy of Cancer), FDA (Food and Drug Administration), and NCI (National Cancer Institute) partnered to address these issues for immunotherapy of cancer. Here…

Cancer ResearchPathologymedicine.medical_specialtyHealth Planning Guidelinesmedicine.medical_treatmentConsensus Development Conferences as TopicStandardized testImmune monitoringt-cell immunity cytokine flow-cytometry cancer vaccine consortium colony-stimulating factor b elispot assay phase-ii trial dendritic cells clinical-trials hiv vaccine harmonization guidelinesMedical OncologyArticleFood and drug administrationNeoplasmsmedicineBiomarkers TumorHumansMedical physicsPersonalized therapySocieties MedicalAntitumor immunitybusiness.industryQuality assessmentUnited States Food and Drug AdministrationCancerInternational AgenciesImmunotherapymedicine.diseaseNational Cancer Institute (U.S.)United StatesOncologyPractice Guidelines as TopicImmunotherapybusiness
researchProduct